Office of Counterterrorism and Emerging Threats, Office of the Commissioner, U.S. Food and Drug Administration.
J Law Med Ethics. 2013 Mar;41 Suppl 1:22-7. doi: 10.1111/jlme.12033.
Preparing for and responding to public health emergencies involving medical countermeasures (MCMs) raise often complex legal challenges and questions among response stakeholders at the local, state, and federal levels. This includes concerns about emergency legal authorities, liability, emergency use of regulated medical products, and regulations that might enhance or hinder public health response goals. In this article, lawyers from the U.S. Department of Health and Human Services' (HHS) Office of the General Counsel (OGC), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA) discuss federal legal tools that are critical to enhancing MCM legal preparedness for public health emergencies, with an emphasis on the legal mechanisms that can be used to facilitate the emergency use of countermeasures. Specifically, the authors describe the Public Readiness and Emergency Preparedness (PREP) Act and Emergency Use Authorization (EUA) authority, outlining the conditions under which these tools can be utilized and providing examples of how they have supported both pre-event (e.g., doxycycline mass dispensing preparedness for anthrax) and intra-event (e.g., 2009 H1N1 influenza pandemic response) activities.
应对涉及医疗对策(MCM)的公共卫生突发事件,常常会给地方、州和联邦各级的应急利益相关者带来复杂的法律挑战和问题。这包括对紧急法定权力、责任、受管制医疗产品的紧急使用以及可能增强或阻碍公共卫生应对目标的法规的关注。在本文中,来自美国卫生与公众服务部(HHS)总法律顾问办公室(OGC)、疾病控制与预防中心(CDC)和食品和药物管理局(FDA)的律师讨论了对增强公共卫生突发事件中 MCM 法律准备至关重要的联邦法律工具,重点是可用于促进对策紧急使用的法律机制。具体来说,作者描述了公共卫生应急准备和防范法案(PREP 法案)和紧急使用授权(EUA)授权,概述了可以利用这些工具的条件,并提供了它们如何支持事前(例如,用于炭疽的强力霉素大规模分发准备)和事件中(例如,2009 年 H1N1 流感大流行应对)活动的例子。